blur de-identification

8
© d-Wise 2015 Page ‹#› d-Wise De-Identification and Anonymization empowering innovation for a healthier world

Upload: d-wise-technologies

Post on 07-Aug-2015

27 views

Category:

Health & Medicine


3 download

TRANSCRIPT

Page 1: Blur De-Identification

© d-Wise 2015 Page ‹#›

d-WiseDe-Identification and Anonymization

empowering innovation for a healthier world

Page 2: Blur De-Identification

© d-Wise 2015 Page ‹#›

d-Wise

Put people in the center of the picture

Define actionable solutions

Achieve success

through small steps

Manage change &

expect to adapt

We are a global technology consulting firm focused on simplifying the life sciences enterprise

Life Science Clients Partners

Page 3: Blur De-Identification

© d-Wise 2015 Page ‹#›

Our Services

Helping clients navigate standards adoption• CDISC Standards• Standards Governance• People, process, and

technology• Development, Use and

Maintenance

StandardsEnabling the business by

leveraging technology• MDR, CDR, EDC, SCE• System Integration• Industry Product

Development• Custom Development• Technology selection and

implementation

TechnologyAligning strategy and

execution for success• Gap Analysis• Process Optimization• Organizational Design• SOP Development• Matching processes to

organizational goals

Process

EXECUTION | PROGRAM & PROJECT MANAGEMENT | ORGANIZATIONAL CHANGE

STRATEGY | ADVISORY | IMPLEMENTATION

Page 4: Blur De-Identification

© d-Wise 2015 Page ‹#›

The d-Wise De-Identification Solution

Blur is the industry-leading solution for delivering de-identified clinical trial data

and protecting patient privacy

“As we expand the availability and sharing of our patient-level clinical trial data to support the improvement of healthcare, we decided to streamline

our processes further. d-Wise’s software solution will help us to achieve this in a way that continues to safeguard the quality of the data.”

James Armbrust, AstraZeneca Head, Clinical Trial Transparency & Disclosure

Page 5: Blur De-Identification

© d-Wise 2015 Page ‹#›

Challenges of Patient-Level Data De-Identification

Historically, de-identification has been a low volume, low visibility process– Minimally maintained tools– Drop-in resourcing– Low priority work– No automation

Growing interest in sharing de-identified data internally and externally is stressing existing processes

Public sensitivity to privacy has never been higher

Page 6: Blur De-Identification

© d-Wise 2015 Page ‹#›

The Value of d-Wise Blur

Reduced de-id costs• 90%

reduction for standardized data

• 70% reduction for other trials

• Decreased outsourcing

Designed for clinical trials• Underst

ands CDISC, SAS and other data types

• Supports PhUSE and emerging rules

• Integrated workflow controls process

• Audit trail captures data activities

Reduced IT costs • Internal

development is time-consuming

• SAS Macro maintenance is challenging

• COTS application enables industry alignment

Page 7: Blur De-Identification

© d-Wise 2015 Page ‹#›

Blur CapabilitiesApplication-Driven with Zero Coding

Integrated Workflow and Controls

Rapid Replication Across Projects

Designed for clinical trials

Page 8: Blur De-Identification

© d-Wise 2015 Page ‹#›

There is tremendous growth in the need to de-identify clinical trial data

Existing tools and approaches are too time-consuming, too labor-intensive and too costly

Blur will enable you to deliver high-quality de-identified clinical trial data to your internal and external

collaborators at lower cost and with faster turnaround time than any other approach available today.